Vipragen Biosciences
PrivateLast Round
Series A
Aug 22, 2023
Total Funding Raised
$658,000
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vipragen Biosciences is a pre-clinical Contract Research Organization (CRO) that provides end-to-end regulatory services for the pharmaceutical, biopharmaceutical, nutraceutical, agrochemical, and medical device industries. The company specializes in drug discovery services, safety studies, general and genetic toxicology, and analytical services to help clients accelerate their drug discovery and development process. Founded in 2012 and headquartered in Mysore, India, Vipragen has a GLP-certified facility and is also accredited by AAALAC and NABL. The company has raised venture capital to expand its operations and serves a global client base with offices in the US, Europe, and Japan.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vipragen Biosciences Comparables
Compare Vipragen Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TheraIndx Lifesciences | 88% | |
| PRADO Preclinical Research and Development Organization Private Limited | 88% | |
| Dabur Research Foundation | 85% |
Vipragen Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 22, 2023 | ||||
| Seed | May 27, 2019 | ||||
| Grant | Aug 30, 2017 |
Vipragen Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Startup Karnataka | Grant |
| Elevate 100 | Grant |
| Karnataka Information Technology Venture Fund | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 237% MoM, reaching 8.2K.
- Jul 26, 2026
Monthly visitors grew 43% MoM, reaching 2.4K.
Vipragen Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vipragen Biosciences's valuation, stock price, and market status.
Is Vipragen Biosciences a public or private company?
Vipragen Biosciences is a private company.
What is the current stock price of Vipragen Biosciences?
Vipragen Biosciences is a private company, so its shares have no public market price. Caplight tracks Vipragen Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vipragen Biosciences worth (valuation)?
Valuation information for Vipragen Biosciences is not publicly available.
Can I buy Vipragen Biosciences stock?
Vipragen Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vipragen Biosciences's last funding round?
Vipragen Biosciences's most recent funding round was Series A on August 22, 2023.
Who are the main investors in Vipragen Biosciences?
Key investors in Vipragen Biosciences include Karnataka Information Technology Venture Fund.
Will Vipragen Biosciences IPO soon?
No public IPO plans have been announced for Vipragen Biosciences.
How can I track Vipragen Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Vipragen Biosciences's shares on secondary markets.